HER2-Negative
2 drugsPredictive biomarker for patient selection in 8 indications
2
Approved Drugs
8
Indications
2
Companies
HER2-Negative is a precision-medicine biomarker linked to 2 FDA-approved targeted drugs from 2 companies, spanning 8 indications including Breast Cancer, Neuroendocrine Tumors, Renal Cell Carcinoma. Explore the targeted therapies, indications, testing methods, and companies developing HER2-Negative drugs below.
Search HER2-Negative Clinical Trials
Search recruiting trials on ClinicalTrials.gov
Drugs Targeting HER2-Negative
| Drug | Company | Therapeutic Area |
|---|---|---|
| AFINITOR | Novartis | Oncology |
| EVEROLIMUS | NATCO | Immunology |
HER2-Negative Indications
Breast Cancer Neuroendocrine Tumors Renal Cell Carcinoma Renal Angiomyolipoma Tuberous Sclerosis Complex Subependymal Giant Cell Astrocytoma Partial-Onset Seizures Seizures